$KROS

Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda LEXINGTON, Mass., September 29, 2026, (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing an

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027 LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: K

Keros Therapeutics (KROS) authorized a $5M share buyback following a $20M milestone payment from Takeda for its elritercept drug. The Phase 3 trial for anaemia began, and the company may repurchase shares based on market conditions. KROS stock rose 3.4% in after-hours trading.

Keros Therapeutics (KROS) received a $20M milestone payment from Takeda for the first patient dosed in the Phase III ELRiSE study. The company has no marketed products and limited revenue, but the payment adds financial flexibility. KROS will distribute 25% of the proceeds to stockholders and use the rest to advance its rinvatercept program. Cash reserves were $257.6M at June 30, 2026, with shares down 46.8% year-to-date.

Keros Therapeutics (KROS) reported a Q2 2026 loss of $1.45 per share, wider than estimates, with revenues falling to zero. The company's focus is on rinvatercept, with clinical trials ongoing. KROS has $257.6M in cash, expected to last until mid-2028. Shares have dropped 46.8% YTD, trading at 37.1X forward sales.

Keros Therapeutics (NASDAQ:KROS) said it received a $20 million development milestone from Takeda (NYSE:TAK) after the first patient was dosed in Phase 3 ELRiSE MDS. The trial compares elritercept with epoetin alfa for anemia in low-to-intermediate-risk MDS. Keros previously got a $200 million upfront payment and may earn over $1.1 billion more milestones plus royalties, and plans to distribute 25% of the $20 million net proceeds to shareholders.

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. kros-20260717 0001664710 FALSE 0001664710 2026-07-17 2026-07-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Keros Therapeutics (Nasdaq: KROS) said Anne Prener, M.D., Ph.D., will join its Board of Directors effective July 1, 2026. The company cited her clinical development and executive leadership experience. Prener is a senior innovation advisor at the University of Copenhagen and a non-executive director of XSpray Pharma, and previously led Imbria Pharmaceuticals.

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. kros-20260623 0001664710 FALSE 0001664710 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):